These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28686318)

  • 21. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Grisanti S; Ferri L; Cavallieri F; Fioravanti V; Vincenzi C; Toschi G; Grisendi I; Sabadini R; Paul JJ; Bauer P; Zedde M; Valzania F
    Mov Disord; 2022 May; 37(5):1117-1118. PubMed ID: 35587629
    [No Abstract]   [Full Text] [Related]  

  • 22. Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease.
    Xiao B; Deng X; Ng EY; Allen JC; Lim SY; Ahmad-Annuar A; Tan EK
    JAMA Neurol; 2018 Jan; 75(1):127-128. PubMed ID: 29131875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features of LRRK2-associated Parkinson's disease in central Norway.
    Aasly JO; Toft M; Fernandez-Mata I; Kachergus J; Hulihan M; White LR; Farrer M
    Ann Neurol; 2005 May; 57(5):762-5. PubMed ID: 15852371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.
    Cogo S; Greggio E; Lewis PA
    Expert Opin Ther Targets; 2017 Aug; 21(8):751-753. PubMed ID: 28609155
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Macías-García D; Periñán MT; Muñoz-Delgado L; Jesús S; Jimenez-Jaraba MV; Buiza-Rueda D; Bonilla-Toribio M; Adarmes-Gómez A; Carrillo F; Gómez-Garre P; Mir P
    Mov Disord; 2022 Jan; 37(1):225-227. PubMed ID: 34859503
    [No Abstract]   [Full Text] [Related]  

  • 28. The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Singleton AB; Gasser T
    Mov Disord; 2020 Apr; 35(4):551-554. PubMed ID: 32065426
    [No Abstract]   [Full Text] [Related]  

  • 29. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
    Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
    Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Macías-García D; Periñán MT; Muñoz-Delgado L; Jesús S; Jimenez-Jaraba MV; Buiza-Rueda D; Bonilla-Toribio M; Adarmes-Gómez A; Carrillo F; Gómez-Garre P; Mir P
    Mov Disord; 2022 May; 37(5):1119-1120. PubMed ID: 35587631
    [No Abstract]   [Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.
    Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucine rich repeat kinase 2: a paradigm for pleiotropy.
    Lewis PA
    J Physiol; 2019 Jul; 597(14):3511-3521. PubMed ID: 31124140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
    Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
    Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.
    Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM
    Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961
    [No Abstract]   [Full Text] [Related]  

  • 37. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for increased completed suicide in first-degree relatives of
    Ortega RA; Groves M; Mirelman A; Alcalay RN; Raymond D; Elango S; Mejia-Santana H; Giladi N; Marder K; Bressman SB; Saunders-Pullman R
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):843-844. PubMed ID: 30409888
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical Features of LRRK2 Carriers with Parkinson's Disease.
    Kestenbaum M; Alcalay RN
    Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
    Melamed E
    Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.